5 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow Bladder Pain Syndrome: new trials by email Literature Review of Bladder Pain Syndrome trials Research Report on Bladder Pain Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Female Microbiome in Patients Undergoing Bladder Instillation Therapy Heparin & Alkalinized Lidocaine Bladder Instillation - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Completed | Walter Reed National Military Medical Center | 29 | 2020-10-01 | 2024-08-14 |
| Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome Heparin & Alkalinized Lidocaine Bladder Instillation, Onabotulinum Toxin A - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Completed | Walter Reed National Military Medical Center | 58 | 2020-09-15 | 2023-10-12 |
| PK and Safety of SI-722 in IC/BPS SI-722, Placebo - Interstitial Cystitis, Bladder Pain Syndrome | Phase 1 / Phase 2 | Completed | Seikagaku Corporation | 33 | 2020-03-30 | 2023-12-29 |
| A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis ASP6294, Placebo - Bladder Pain Syndrome, Interstitial Cystitis | Phase 2 | Completed | Astellas Pharma Europe B.V. | 119 | 2017-09-28 | 2024-10-31 |
| Efficacy and Safety of AQX-1125 in IC/BPS AQX-1125, Placebo - Interstitial Cystitis, Bladder Pain Syndrome | Phase 2 | Completed | Aquinox Pharmaceuticals (Canada) Inc. | 69 | 2013-06-01 | 2017-09-05 |
Cystitis, Interstitial (5) · Communicable Diseases (1)
Cystitis (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urologic Diseases (5) · Disease Attributes (1) · Infections (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Heparin (2) · 4-(4-(aminomethyl)-7a-methyl-1-methylideneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexan-1-ol (1) · onabotulinum toxin A (1)
Walter Reed National Military Medical Center (2) · Aquinox Pharmaceuticals (Canada) Inc. (1) · Astellas Pharma Europe B.V. (1) · Seikagaku Corporation (1)
United States (4) · Belgium (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Latvia (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · United Kingdom (1)
Eva K Welch, MD MS (1) · Stephen B Shrewsbury, MD (1)
2016 (1)